Previous article Next article

The US FTC charges a $10 Million fine to a company that illegally maintained a monopoly over the Opioid Addiction Treatment Suboxone (Indivior)

Indivior, Inc. to Pay $10 Million to Consumers, Settling FTC Charges that the Company Illegally Maintained a Monopoly over the Opioid Addiction Treatment Suboxone* FTC alleges company used anticompetitive tactics to impede competition from lower-cost generics Indivior, Inc. has agreed to pay $10 million to settle Federal Trade Commission charges that it violated antitrust laws through a deceptive scheme to thwart lower priced generic competition with its branded opioid replacement therapy drug

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC charges a $10 Million fine to a company that illegally maintained a monopoly over the Opioid Addiction Treatment Suboxone (Indivior), 24 July 2020, e-Competitions Preview, Art. N° 95994

Visites 43

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues